nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-742E574D·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.1 Basic medicine·Subfield: Neurology·Basis: Full text·Type: Cross-sectional study

The Target ALS Global Natural History Study: Cross-platform proteomics to accelerate biofluid biomarker and drug target discovery in amyotrophic lateral sclerosis.

Yasui et al.Yasui, Weatherill, Dugom et al.·2026·medRxiv : the preprint server for health sciences·10.64898/2026.06.13.26355379 ↗

Primary claim

We identified 2,875 proteins in CSF and 1,118 proteins in plasma and identified known and novel differentially expressed proteins (DEPs) between controls and sALS, some of which were orthogonally validated using immunoassay.

Supported · cross-sectional discovery with modest cohorts and validation limited to three selected proteins
In brief

Matched-platform ALS proteomics yields a useful discovery resource, but unadjusted case-control analyses limit confidence in disease-specific biomarker claims.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal, rapidly progressive neurodegenerative disease of motor neurons for which therapeutics are limited. Improved biomarkers are imperative to improve patient care and therapeutic development. Here, we employed 35-plex isobaric tandem mass tag labeling based on isobutyl-proline reporter group (TMTpro) to perform unbiased proteomic analysis of cerebrospinal fluid (CSF) and plasma from control (n= 28, n= 31) and sporadic ALS (sALS) (n= 39, n= 41), from the Target ALS Global Natural History Study (TALS GNHS). We identified 2,875 proteins in CSF and 1,118 proteins in plasma and identified known and novel differentially expressed proteins (DEPs) between controls and sALS, some of which were orthogonally validated using immunoassay. Comparison of TMTpro-MS and Olink proximity extension assay proteomics revealed common and non-overlapping differentially expressed proteins illustrating strengths unique to each platform. This initial cross-sectional proteomic study of biofluids from the TALS GNHS, with unrestricted availability of study results to the research community, highlights the potential of this resource as a potent platform for ALS biomarker discovery.

Key Claims

Primary finding · Supported

We identified 2,875 proteins in CSF and 1,118 proteins in plasma and identified known and novel differentially expressed proteins (DEPs) between controls and sALS, some of which were orthogonally validated using immunoassay.

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

cross-sectional discovery with modest cohorts and validation limited to three selected proteins

Abstract
Quote verified
Secondary · Tentative

Comparison of TMTpro-MS and Olink proximity extension assay proteomics revealed common and non-overlapping differentially expressed proteins illustrating strengths unique to each platform.

different protein libraries and sample subsets limit inference from differential-expression overlap

Abstract
Quote verified
Secondary · Supported

A total of 149 proteins were increased and 148 proteins decreased in sALS compared with healthy controls.

directly reported FDR-controlled comparison without covariate adjustment

Results, “Proteomic analysis of differentially expressed proteins in sALS CSF”
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Matched cross-platform biofluid profiling

TMTpro-MS and Olink were compared on overlapping CSF and plasma samples, allowing direct description of common and non-overlapping detected proteins and DEPs.

↳ Results, “Comparison of 35plex TMTpro-MS to antibody-based proteomics”

#methodological rigour

Detailed contemporary proteomic workflow

The Methods specify immunodepletion, 35-plex labelling, high-pH fractionation, FAIMS-enabled Orbitrap acquisition, Percolator FDR control, pooled-reference normalisation, and BH correction.

↳ Methods, protein preparation through “Statistical analysis”

#methodological rigour

Independent validation reports mixed results

ELISA testing in a separate cohort reproduced increased CKM and SERPINA3 while openly reporting that CHAD did not replicate.

↳ Results, “ELISA validation of 35plex TMTpro-MS hits,” Figure 5

Limitations

#methodological rigour

Disease comparisons lack covariate adjustment

The primary sALS-versus-control analyses use Welch tests without adjustment for available age, sex, site, or clinical variables, limiting disease-specific interpretation of the DEPs.

↳ Methods, “TALS GNHS Cohort” and “Statistical analysis”

#reporting

Sensitivity claims exceed comparative design

DEP totals from different protein libraries and unequal sample subsets are treated as evidence of superior platform sensitivity without a common reference standard.

↳ Results, cross-platform and tissue-enrichment sections; Conclusions, paragraphs 5–6

#application pathway

Validation and generalisation remain limited

Only three proteins underwent independent ELISA testing, one did not replicate, and no site-, demographic-, or disease-stage-stratified analyses are reported.

↳ Methods, “Validation Cohort”; Results, “ELISA validation,” Figure 5

Does this match your read? Add your assessment ↓

Nabu Commentary

The matched-platform profiling and independent ELISA cohort make this a useful discovery resource, and the detailed analytical workflow supports reproducibility. The main methodological constraint is that disease-group comparisons rely on unadjusted Welch tests despite available demographic and clinical variables. Claims of superior platform sensitivity receive less weight because DEP counts arise from different protein libraries and unequal participant subsets rather than a shared reference standard. The paper is therefore most persuasive as a candidate-generation and data-sharing study, not as evidence of clinically qualified biomarkers or general platform superiority.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.0±0.2

Contribution
3.7

The study contributes a matched-sample comparison of TMTpro-MS and Olink in CSF and plasma, selected independent-cohort ELISA checks, and a shared proteomic resource. Its advance remains candidate-level because the cohorts are modest and only two of three assayed candidates replicated.

Abstract; Results, “Comparison of 35plex TMTpro-MS to antibody-based proteomics” and “ELISA validation of 35plex TMTpro-MS hits”

“revealed common and non-overlapping differentially expressed proteins”

Methodological Rigour
2.5

The laboratory workflow, pooled reference, peptide-level FDR control, missing-data rule, and BH correction are described in detail. The primary comparisons nevertheless rely on unadjusted Welch tests, and exclusion of group-specific detections plus the smaller Olink subset introduces uncertainty about selection and disease attribution.

Methods, “Quantification and normalization” and “Statistical analysis”; Results, CSF/plasma proteomic analyses and cross-platform comparison

“Pairwise comparisons between disease and control groups were conducted using Welch’s t-test”

Reporting
3.4

The manuscript follows a coherent sequence from within-platform findings to cross-platform overlap and ELISA validation. Repeated claims of superior sensitivity are stronger than comparisons of DEP counts across unequal panels and sample subsets support.

Results, “Comparison of 35plex TMTpro-MS to antibody-based proteomics”; Conclusions, paragraphs 5–6

“TMTpro-MS showed superior sensitivity over Olink”

Positioning
2.8

The Introduction engages established neurofilament, chitinase, TDP-43, and prior proteomic literature, while the Results disclose CHAD non-replication and plasma ratio compression. The conclusions do not trace the implications of unadjusted cross-sectional comparisons, healthy-only controls, or modest samples into the disease-associated biomarker interpretation.

Introduction; Results, “ELISA validation”; Conclusions

“Further studies are required to ascertain their role in disease”

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

Protein-count definitions are not reconciled between the initial analyses and cross-platform comparisons, and the unrestricted-access description requires qualification because portal approval is required.

Conflict of interest: not stated · Ethics approval: declared · Preregistration: declared · Data availability: declared

Reference IntegrityClean

45 references in manuscript 45 of 45 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Motor neuron disease
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesSmall
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

Differential expression rests on one cross-sectional discovery cohort, and only two of three ELISA-tested candidates were confirmed in a small external pilot cohort without larger or context-of-use validation.

From the paper
“The accessibility and ease of collecting plasma is desirable for next-generation ALS clinical biomarkers to facilitate diagnosis, prognosis, and screening for clinical trial enrollment.”

The paper names diagnosis, prognosis, and trial-enrollment screening as real-world uses for the ALS biomarkers its candidates could become, but never names who would act on these findings.

Pathway

ALS researchers, trial teams, and assay developers could develop validated candidates like SERPINA3 and CKM into diagnostic, prognostic, and pharmacodynamic biomarkers for trial enrollment and therapy development.

Barrier

Only two of three tested candidates replicated in a small external cohort, and larger longitudinal validation against defined clinical contexts of use is still required.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity

    Selvaraj, Livesey, Zhao, et al. · 2018 · Basic medicine

    Primary claim

    increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  2. Astrocytes regulate axonal mitochondrial transport deficits in C9ORF72 amyotrophic lateral sclerosis motor neurons

    Stavrou, Heffernan, Carter, et al. · 2026 · Basic medicine

    Primary claim

    human-induced pluripotent stem-cell-derived astrocytes carrying the C9ORF72 mutation disrupt mitochondrial axonal transport and mitochondrial function in cocultured motor neurons (MNs)

    Supported
    Evidence Score
    3.1±0.1
    Reliability
    Caveats
  3. Alzheimer's Disease Co-Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis

    Kasper, Lehto, Jürs, et al. · 2026 · Clinical medicine

    Primary claim

    CSF p-tau and total-tau levels were strongly associated with domain-specific cognitive performance.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    Concerns

How the rubric works →